SCHEMBL17375905

SCHEMBL17375905

CC(C)(C)OC(=O)N(Cc1ccccc1)C[C@@H]1CO1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC2 Q92769 1/20 0.50
NCOR2 Q9Y618 1/20 0.50
CTSL P07711 1/20 0.44
CTSB P07858 1/20 0.44
CTSS P25774 1/20 0.44
AKT1 P31749 2/20 0.43
OXTR P30559 4/20 0.42
AVPR1A P37288 4/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
LMNA P02545 1/20 0.41
RECQL P46063 1/20 0.41
BACE1 P56817 1/20 0.40
ALDH1A1 P00352 2/20 0.40
HSD11B1 P28845 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17375904 1.00 HDAC3 (0.50) HDAC3HDAC1HDAC2NCOR2CTSL
SCHEMBL9223888 0.85 HDAC1 (0.51) HDAC3HDAC1HDAC2NCOR2CTSL
SCHEMBL334445 0.82 MEN1 (0.50) OXTRAVPR1AMEN1KMT2ALMNA
SCHEMBL8651536 0.82 HDAC3 (0.48) HDAC3HDAC1HDAC2NCOR2CTSL
SCHEMBL7405554 0.81 HDAC3 (0.55) HDAC3HDAC1HDAC2NCOR2CTSL
SCHEMBL23288368 0.80 LMNA (0.60) HDAC3HDAC1HDAC2NCOR2CTSL
SCHEMBL2722481 0.79 HDAC3 (0.53) HDAC3HDAC1HDAC2NCOR2CTSL
SCHEMBL2834319 0.79 HDAC3 (0.55) HDAC3HDAC1HDAC2NCOR2CTSL
SCHEMBL29109901 0.79 HDAC3 (0.55) HDAC3HDAC1HDAC2NCOR2CTSL
SCHEMBL11160181 0.79 OXTR (0.53) HDAC3HDAC1OXTRAVPR1AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170198006-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-07-13 US disclosed
US-20170198006-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-07-13 US disclosed
US-20170198006-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-07-13 US disclosed
EP-3160477-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-05-03 EP disclosed
WO-2015200680-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2015-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170198006-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 HDAC3 90/4885HDAC1 40/4885HDAC2 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.